Receiving a diagnosis of Huntington’s disease (HD) can be overwhelming, not only for the individual but also for their entire family. HD is a progressive neurodegenerative disorder, meaning it gradually worsens over time, affecting movement, thinking, and behavior. While there is currently no cure, proactive planning can significantly improve the quality of life for patients and their caregivers throughout the disease journey. This article explores the various aspects of HD progression and how planning ahead can help families navigate the challenges.

Understanding Huntington’s Disease Progression

Huntington’s disease is caused by a genetic mutation that leads to damage in specific areas of the brain, particularly the basal ganglia (Herrero et al., 2002). This damage underlies the wide range of symptoms experienced by patients. The disease is progressive, meaning symptoms typically appear subtly at first and become more pronounced and debilitating over many years, usually 15 to 20 years after the onset of symptoms (Ghosh & Tabrizi, 2018).

Researchers are developing frameworks to better understand and even stage the progression of HD, recognizing that biological changes can occur decades before obvious clinical signs appear (Tabrizi et al., 2022). While this research staging is primarily for clinical trials, clinically, HD progression is often understood in broad phases:

Early Stage: Subtle changes in movement, thinking, or mood may occur. The individual can usually manage daily activities independently.
Middle Stage: Movement disorders become more noticeable. Cognitive and behavioral symptoms may interfere with work and daily tasks. Assistance is increasingly needed.
Late Stage: The individual experiences significant physical, cognitive, and behavioral challenges. They may have difficulty walking, speaking, and swallowing.

As the disease progresses, patients often become entirely dependent on caregivers for daily needs, including bathing, dressing, and eating. Juvenile Huntington's disease (JHD), which affects children and adolescents, is rare and typically progresses faster with specific symptoms like rigidity, dystonia, and epilepsy (Oosterloo et al., 2024).

Understanding the potential trajectory of the disease, while difficult, is a crucial first step in preparing for the future.

Why Planning Ahead is Essential in HD

Given the progressive nature of Huntington’s disease and its impact on cognitive abilities, planning for future care and decisions while the individual still has the capacity to participate is invaluable. Advanced care planning (ACP) is highly recommended and involves discussing future medical care preferences with healthcare providers and family members (Supporting Info, Harrison et al., 2022).

Planning ahead helps ensure that the patient's wishes and values guide decisions about their care as the disease advances and they may no longer be able to express them clearly (Farag et al., 2023). It empowers the patient and provides clarity and reassurance to caregivers and clinicians (Farag et al., 2023).

Factors associated with having advance directives in HD include being older, having a more advanced disease stage, and higher educational attainment. However, studies show that the prevalence of advance directives among people with HD is surprisingly low, comparable to the general population, despite the severity and long course of the disease (Downing et al., 2018). This highlights the need for healthcare providers to initiate these conversations early (Downing et al., 2018).

Importantly, engaging in advance care planning has not been shown to negatively impact a patient's quality of life or increase suicidal thoughts or behaviors, which are unfortunately elevated in the HD population compared to other neurological disorders (Sokol et al., 2023).

Key Areas for Planning and Preparation

Preparing for the progression of Huntington’s disease involves addressing various aspects of life.

Medical and Healthcare Planning

Advance Care Planning (ACP): Discuss your preferences for future medical treatments, including life-sustaining interventions, pain management, and comfort care. Formalize these wishes through legal documents like a living will or durable power of attorney for healthcare (Downing et al., 2018; Farag et al., 2023).
Choosing a Healthcare Proxy: Designate a trusted person to make healthcare decisions on your behalf if you become unable to do so.
Early Discussion with Providers: Initiate conversations about the disease trajectory and future care needs with your doctors and the multidisciplinary HD care team as early as possible (Supporting Info, Harrison et al., 2022). Multidisciplinary teams are crucial for providing comprehensive care for the complex symptoms of HD (Edmondson & Goodman, 2017; Harrison et al., 2022).
End-of-Life Care: While challenging, discussing end-of-life care wishes is important. Common causes of death in HD include complications like pneumonia and, sadly, suicide, underscoring the need for comprehensive medical and emotional planning (Supporting Info). Palliative care practices can be integrated throughout the disease course, not just at the very end, to focus on patient comfort and quality of life (Harrison et al., 2022).

Caregiving and Daily Living

Anticipating Needs: Understand that as the disease progresses, the need for assistance with daily activities will increase (Supporting Info). Plan for home modifications, adaptive equipment, and potential future residential care needs.
Caregiver Preparation: Caregivers play a vital role and require support and preparation. Discuss roles and responsibilities within the family. Seek education on managing HD symptoms and providing physical care. Caregiver well-being is essential and can be impacted by the demands of caring for someone with a neurodegenerative condition (Maras et al., 2018).
Building a Support Network: Identify family, friends, and community resources that can provide assistance and respite for caregivers.

Financial and Legal Planning

Legal Documents: Establish legal documents such as a will, durable power of attorney for finances, and potentially trusts to manage assets and ensure your wishes are carried out.
Financial Planning: Assess financial resources, including insurance, disability benefits, and savings, to cover future medical expenses, caregiving costs, and living expenses. Consult with a financial advisor experienced in long-term care planning.

Emotional and Mental Health Support

Addressing Psychiatric Symptoms: HD often involves psychiatric symptoms like depression, anxiety, irritability, and obsessive-compulsive behaviors (Ghosh & Tabrizi, 2018). These should be addressed as part of the overall care plan.
Emotional Well-being: The emotional toll of HD on patients and families is significant. Seek counseling or therapy to cope with the diagnosis and its progression.
Support Groups: Connecting with other families affected by HD through support groups can provide invaluable emotional support, practical advice, and a sense of community.

Looking Ahead: Hope and Research

While preparing for the challenges of HD progression is essential, it's also important to acknowledge the ongoing research efforts. Scientists are tirelessly working to understand the disease mechanisms and develop disease-modifying therapies aimed at slowing or even preventing the progression of HD (Ross & Tabrizi, 2011; Ghosh & Tabrizi, 2018; Wild & Tabrizi, 2014). Although clinical trials have faced setbacks, such as the termination of the tominersen trial, research continues to explore various targets, including reducing the mutated huntingtin protein, enhancing cellular repair, and improving brain function (Tabrizi et al., 2022). Participation in research, when appropriate, offers hope for future generations.

Conclusion

Planning ahead for the progression of Huntington’s disease is a continuous process that involves open communication, informed decision-making, and building a strong support system. By addressing medical, caregiving, financial, legal, and emotional needs proactively, patients and their families can face the future with greater confidence and ensure the best possible quality of life throughout the HD journey. Engaging with healthcare providers early and utilizing available resources are key steps in this important preparation.

References

Downing, N. R., Goodnight, S., Chae, S., Perlmutter, J. S., McCormack, M., Hahn, E., Barton, S. K., & Carlozzi, N. (2018). Factors Associated With End-of-Life Planning in Huntington Disease. Journal of Pain and Symptom Management, 55(1), 75–82.e2.
Edmondson, M. C., & Goodman, L. (2017). Contemporary health care for Huntington disease. Seminars in Neurology, 37(06), 664–672.
Farag, M., Salanio, D. M., Hearst, C., Rae, D., & Tabrizi, S. J. (2023). Advance Care Planning in Huntington's Disease. Journal of Huntington's Disease, 12(4), 453–460.
Ghosh, R., & Tabrizi, S. J. (2018). Huntington disease. In S. H. Subramony (Ed.), Handbook of Clinical Neurology (Vol. 147, pp. 255–270). Elsevier.
Harrison, M. B., Morrissey, D. L., Dalrymple, W. A., D’Abreu, A., & Daly, F. N. (2022). Primary Palliative Care in Huntington’s Disease. Journal of Palliative Medicine, 25(5), 766–771.
Herrero, M.-T., Barcia, C., & Navarro, J. M. (2002). Functional anatomy of thalamus and basal ganglia. Child's Nervous System, 18(9-10), 486–494.
Maras, A., Schroder, C. M., Malow, B. A., Findling, R. L., Breddy, J., Nir, T., Shahmoon, S., Zisapel, N., & Gringras, P. (2018). Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 57(9), 721-729.e2.
Oosterloo, M., Touze, A., Byrne, L. M., Achenbach, J., Aksoy, H., Coleman, A., Lammert, D., Nance, M., Nopoulos, P., Reilmann, R., Saft, C., Santini, H., Squitieri, F., Tabrizi, S., Burgunder, J.-M., & Quarrell, O. (2024). Clinical Review of Juvenile Huntington's Disease. Movement Disorders Clinical Practice, 11(2), 163–173.
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., Reilmann, R., Unschuld, P. G., Wexler, A., Margolis, R. L., & Tabrizi, S. J. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 10(4), 204–216.
Ross, C. A., & Tabrizi, S. J. (2011). Huntington’s disease: from molecular pathogenesis to clinical treatment. The Lancet Neurology, 10(9), 837–848.
Sokol, L. L., Troost, J. P., Bega, D., Kluger, B. M., Prigerson, H. G., Nance, M., Frank, S., Perlmutter, J. S., Dayalu, P., Cella, D., & Carlozzi, N. E. (2023). Advance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study. Journal of Pain and Symptom Management, 65(1), 32–41.
Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R. (2022). Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. The Lancet Neurology, 21(7), 645–658.
Tabrizi, S. J., Schobel, S., Gantman, E. C., Mansbach, A., Borowsky, B., Konstantinova, P., Mestre, T. A., Panagoulias, J., Ross, C. A., Zauderer, M., Mullin, A. P., Romero, K., Sivakumaran, S., Turner, E. C., Long, J. D., & Sampaio, C. (2022). A biological classification of Huntington's disease: the Integrated Staging System. The Lancet Neurology, 21(7), 632–644.
Wild, E. J., & Tabrizi, S. J. (2014). Targets for future clinical trials in Huntington's disease: what's in the pipeline? Expert Review of Neurotherapeutics, 14(7), 717–721.

Planning Ahead: Preparing for Life with Huntington’s Disease